Physician profile
Tonya J Devaul
NPI 1154869766
$1,462.30
in general payments reported to CMS, 2019-2025
13 companies · $528 in 2025
The $528 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $358 · 2023: $256 · 2024: $320 · 2025: $528.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,104.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,104.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $644.38 | 2022-2025 | |
| Janssen Biotech, INC. | $168.63 | 2022-2024 | Stelara, Simponi Aria, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $108.73 | 2023-2025 | Entyvio, Eohilia |
| Regeneron Healthcare Solutions, INC. | $86.38 | 2022-2025 | Dupixent |
| Madrigal Pharmaceuticals | $81.93 | 2025 | Rezdiffra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $73.22 | 2022-2025 | Xifaxan |
| Genzyme Corporation | $69.62 | 2022-2025 | |
| Ardelyx, INC. | $64.91 | 2023-2025 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $58.55 | 2024-2025 | Voquezna |
| Lilly USA, LLC | $30.59 | 2023 | |
| Novo Nordisk INC | $28.17 | 2023-2024 | Wegovy |
| Celgene Corporation | $25.30 | 2024 | Zeposia |
| Merck Sharp & Dohme LLC | $21.89 | 2023 | Dificid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tonya Devaul listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.